A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and exhibits the following symptoms: hepatitis B viral particles and hepatitis B viral DNA in the serum, hepatitis B virus (HBV) envelope and HBV e proteins in the serum, expression of HBV core and HBV envelope proteins in the liver but not in the kidney, heart, lung, brain, pancreas, spleen, stomach or intestine tissues. The animal disease model may develop hepatocellular carcinoma, exhibiting an elevated level of alanine aminotransferase as compared to a control animal without the hepatitis B virus genome in the liver cells thereof, and liver pathological symptoms such as tumor nodules, dysplasia, inflammatory infiltrates, necrosis and fibrosis.